Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Robert M. Rifkin, MD, Sudhir Manda, MD, Stephen J Noga, MD PhD, Habte A Yimer, MD, Saulius K. Girnius, MD, Ruemu Ejedafeta Birhiray, MD, Christopher A. Yasenchak, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 1882.

https://doi.org/10.1182/blood-2019-124747

Published: 2019

Journal Articles

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Luke Mountjoy, DO, Daniel Almquist, MD, Henry Ofori, Pharm D, RPh, Marlene Girardo, MS, Margaret McCallen, Pharm D, RPh

Blood (2019) 134 (Supplement_1): 3262.

https://doi.org/10.1182/blood-2019-128644

Published: 2019

Journal Articles

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Stephen J Noga, MD PhD, Robert M. Rifkin, MD, Sudhir Manda, MD, Ruemu Ejedafeta Birhiray, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 3168.

https://doi.org/10.1182/blood-2019-124784

Published: 2019

Journal Articles

Clinical and immunological features in a cohort of patients with partial DiGeorge syndrome followed at a single center

Giuliana Giardino, Nesrine Radwan, Patra Koletsi, Deborah M. Morrogh, Stuart Adams, Winnie Ip, Austen Worth, Alison Jones, Imke Meyer-Parsonson, H. Bobby Gaspar, Kimberly Gilmour, E. Graham Davies, Fani Ladomenou

Blood (2019) 133 (24): 2586–2596.

https://doi.org/10.1182/blood.2018885244

Published: 2019

Journal Articles

Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Catherine Kendall Major, BS, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Nicholas J Short, MD, Naval G. Daver, MD, Elias J. Jabbour, MD, Richard E Champlin, MD, Guillermo Garcia-Manero, MD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Sherry A. Pierce, BSN, BA, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3976.

https://doi.org/10.1182/blood-2018-99-119892

Published: 2018

Journal Articles

Atypical Chronic Myeloid Leukemia

Chandralekha Ashangari, MD, Praveen K. Tumula, MD

Blood (2018) 132 (Supplement 1): 5455.

https://doi.org/10.1182/blood-2018-99-110189

Published: 2018

Journal Articles

Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study

Anastasia Tsagianni, MD, Margaret V. Ragni, MD MPH, Diane M. Comer, BS, Jonathan G. Yabes, PhD

Blood (2018) 132 (Supplement 1): 1179.

https://doi.org/10.1182/blood-2018-99-111731

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis

Max J Gordon, MD, Stephen M Amrock, SM, MD, Xavier Issac Rivera, BS, Spencer James, MD, Sudhir Manda, MD, Stephen E Spurgeon, MD, Daniel Persky, MD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 918.

https://doi.org/10.1182/blood.V130.Suppl_1.918.918

Published: 2017

Journal Articles

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

Steven P Treon, MDPhDFRCP, Kirsten Meid, MPH, Joshua Gustine, Kurt S. Bantilan, MPH, Toni Dubeau, NP, Patricia Severns, NP, Guang Yang, PhD, Lian Xu, Christopher Patterson, MAcc, Irene M Ghobrial, MD, Jacob Laubach, MD, Zachary Hunter, PhD, Jorge J. Castillo, MD, Maria L. Palomba, MD, Ranjana H. Advani, MD

Blood (2017) 130 (Supplement 1): 2766.

https://doi.org/10.1182/blood.V130.Suppl_1.2766.2766

Published: 2017

Journal Articles

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Wojciech Jurczak, Simon Rule, MD, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD

Blood (2017) 130 (Supplement 1): 2778.

https://doi.org/10.1182/blood.V130.Suppl_1.2778.2778

Published: 2017

Journal Articles

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, Saulius Girnius, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Cristina J. Gasparetto, MD, Chatchada Karanes, MD, Matthew A. Lunning, DO, Jeffrey V. Matous, MD, Ruben Niesvizky, MD, Chaim Shustik, MD, Robert K. Stuart, MD, Jason Lih, PhD, Yihua Lee, PhD, Zeena Salman, Thorsten Graef, MD PhD, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 3111.

https://doi.org/10.1182/blood.V130.Suppl_1.3111.3111

Published: 2017

Journal Articles

A Phase 1-2 Dose-Escalation and Cohort- Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies

Ajay K. Gopal, MD, Rod Ramchandren, MD, Nashat Y. Gabrail, Manish R Patel, MD, Ding Wang, MDPhD, Langdon L Miller, MD, Vikas Goel, PhD, Gary G Chiang, PhD, Kevin R Webster, PhD, Sam Sperry, PhD, Debra T Vallner, PhDMBA, Cara Casseday, BSc MBA, Jeremy Barton, MBBS

Blood (2017) 130 (Supplement 1): 4624.

https://doi.org/10.1182/blood.V130.Suppl_1.4624.4624

Published: 2017

Journal Articles

Feeding the Fire: The Comorbid and Inflammatory Backdrop of Clonal Hematopoiesis of Indeterminate Potential (CHIP) By Mutation Subtype

Elina K Cook, Terumi Izukawa, Sherylan Young, Gili Rosen, Mina Jamali, Brooke Snetsinger, Dylan Johnson, Eva Bain, Jamie Hilland, Jonah Buckstein, Janika Francis, Bushra Momtaz, Rena Buckstein, MD, Michael J. Rauh, MD PhD

Blood (2017) 130 (Supplement 1): 426.

https://doi.org/10.1182/blood.V130.Suppl_1.426.426

Published: 2017

Journal Articles

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients

Robert J Charnigo, MS, Beesan Tan, PhD, Denis Rybin, PhD, Debra D Pittman, MS, Krupa M. Sivamurthy, MBBS, MD, David Beidler, PhD, Nicholas Clarke, PhD

Blood (2017) 130 (Supplement 1): 3558.

https://doi.org/10.1182/blood.V130.Suppl_1.3558.3558

Published: 2017

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality

Mohamed L Sorror, MD MSc, Barry E. Storer, PhD, Mahmoud Elsawy, MD MSc, Amir T Fathi, MD, Andrew Brunner, MD, Aaron T. Gerds, MD MS, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD, Bruno C. Medeiros, MD, Paul Shami, MD, Esteban Peña, MD, Shylo Wardyn, MS, Jennifer Whitten, MPH, Hannah Frenkel, BS, Jeannine McCune, PharmD, Stephanie J. Lee, MD MPH, Elihu H. Estey, MD

Blood (2015) 126 (23): 532.

https://doi.org/10.1182/blood.V126.23.532.532

Published: 2015

Journal Articles

Novel Fanci Mutations in Fanconi Anemia with Vacterl Association

Blanche P Alter, MD MPH, Bari J Ballew, PhD, Neelam Giri, MD, Settara Chandrasekharappa, PhD, Najim Ameziane, PhD, Johan de Winter, PhD, Sharon A Savage, MD

Blood (2015) 126 (23): 4780.

https://doi.org/10.1182/blood.V126.23.4780.4780

Published: 2015

Journal Articles

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Andrew Spencer, MD, Sung-Soo Yoon, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Shannon Morris, MD, PhD, Deborah Smith, PharmD, Steven J. Freedman, MD, PhD, Richard Brigandi, MD, PhD, Allen Oliff, MD, Joanna B. Opalinska, MD, PhD, Christine Chen, MD

Blood (2011) 118 (21): 1856.

https://doi.org/10.1182/blood.V118.21.1856.1856

Published: 2011

Journal Articles

Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Rainer Storb, MD, Paul J Martin, MD, Smita Bhatia, MD, MPH, Richard T. Maziarz, MD, Michael A. Pulsipher, MD, Michael T. Maris, MD, H. Joachim Deeg, M.D., Frederick R. Appelbaum, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Ted A. Gooley, PhD

Blood (2011) 118 (21): 156.

https://doi.org/10.1182/blood.V118.21.156.156

Published: 2011

NARROW

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Clinical and immunological features in a cohort of patients with partial DiGeorge syndrome followed at a single center

Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Atypical Chronic Myeloid Leukemia

Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

A Phase 1-2 Dose-Escalation and Cohort- Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies

Feeding the Fire: The Comorbid and Inflammatory Backdrop of Clonal Hematopoiesis of Indeterminate Potential (CHIP) By Mutation Subtype

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality

Novel Fanci Mutations in Fanconi Anemia with Vacterl Association

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only